AP
BMRN icon

Aspect Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Aspect Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.38K Buy
59
+16
+37% +$876 ﹤0.01% 469
2026
Q1 		$2.43K Buy
+43
New +$2.51K ﹤0.01% 462

Other funds holding BMRN

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
EIP
Easterly Investment Partners Beverly, Massachusetts $1.97B AUM 25.87% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
CF
Covea Finance Paris, France $3.17B AUM 35.01% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Aspect Partners's BMRN Position: Q2 2026 in Review

Aspect Partners increased its BioMarin Pharmaceuticals (BMRN) stake by 37% in Q2 2026, buying an estimated $876 and bringing the position to 59 shares worth $3.38K. The position accounts for ﹤0.01% of the portfolio, ranked #469.

Aspect Partners first reported a position in BMRN in Q1 2026 and has held it in 2 quarters since. 108 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Aspect Partners held 59 shares of BioMarin Pharmaceuticals worth $3.38K as of Q2 2026.
  • Aspect Partners bought 16 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $876.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Aspect Partners's portfolio in Q2 2026, its #469 holding.
  • Aspect Partners first reported a position in BioMarin Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 108 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Aspect Partners's 13F filing for Q2 2026, filed 16 Jul 2026.